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INTRODUCTION 
 
Rheumatoid Arthritis (RA) is a chronic inflammatory disease 
characterised by symmetric peripheral polyarthritis, resulting in joint damage 
and physical disability. Its aetiology is unknown. It is the commonest form of 
chronic inflammatory arthritis. Being a systemic disease, it results in a wide 
variety of extraarticular manifestations, like fatigue, subcutaneous nodules, 
pulmonary  involvement, pericarditis, peripheral neuropathy,vasculitis, and 
hematological abnormalities.1 
Many reports in  history describes a disease condition similar to 
Rheumatoid Arthritis, including those by Hippocrates2, Greek physician 
Arataeus, Caesar’s physician Scribonius, the Byzantine physician Soranus, 
Emperor Constantine IX’s adviser Michael Psellus345, and Charaka from 
India, and also translation from Latin by Short, of Sydenhams (1676)6. The 
first explanation of Rheumatoid Arthritis accepted by modern medicine was 
seen in the dissertation of Augustin JacobLandré-Beauvais from the year 
1800. He described acute onset of polyarthritis in a 35 year old female, which 
slowly ceased , resulting in  wrist and hands deformities, which recurred.7 
Archibald Garrod coined the term Rheumatoid Arthritis in 1859.8 But the 
term Rheumatoid Arthritis came into use in 1941.9 
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AIM AND OBJECTIVES 
 
 
To know 
 
 
1) The prevalence of microalbuminuria in patients having  rheumatoid 
arthritis. 
 
2) The relationship between microalbuminuria and disease activity in 
rheumatoid arthritis as assessed by parameters like DAS28 
score,ESR,CRP,RA Factor and presence of active symptoms. 
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DIAGNOSIS 
 
  
Diagnosis of Rheumatoid Arthritis is by the use of Modified American 
College of Rheumatology (ACR) criteria (1987)10 
  
Modified ACR criteria-1987 
 
CRITERION DEFINITION 
1.Morning stiffness Morning stiffness in and around the joints, lasting at least 1 hour before maximal improvement 
2.Arthritis of 3 or more 
joint areas 
At least 3 joint areas simultaneously having had soft tissue 
swelling or fluid (not bony overgrowth alone) observed by 
a physician. The 14 possible joint areas are right or left 
PIP, MCP,wrist, elbow, knee, ankle and MTP joints 
3.Arthritis of hand joints At least 1 joint area swollen (as described above) in PIP, MCP,or Wrist joint . 
4.Symmetric arthritis 
Simultaneous involvement of the same joint areas (as 
definedin 2) on both sides of the body (bilateral 
involvement of PIPs, MCPs, or MTPs is accepted without 
absolute symmetry) 
5.Rheumatoid nodules 
Subcutaneous nodules over bony prominences or extensor 
surfaces or in juxtaarticular regions, observed by a 
physician 
6.Serum rheumatoid 
factor 
Detection of abnormal amounts of serum rheumatoid 
factor by any method for which the result has been 
positive in <5% of normal control subjects 
7.Radiolographicchanges 
radiolographic changes typical of RA seen on 
posteroanterior hand and wrist radiographs, which must 
include erosions or unequivocal bony decalcification 
localized in or most marked near the involved joints 
(osteoarthritis changes alone do not qualify) 
  
 4 or more out of these 7 criteria is diagnostic of rheumatoid arthritis. 
Criteria 1 to 4 should be present for 6 weeks or more. Patients with 2 clinical 
diagnoses are not excluded. 
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This has a sensitivity of 92%, and specificity of 89.3%. 
Generally, most of the serologic studies are neither sensitive nor specific 
for Rheumatoid Arthritis but anti-cyclic citrullinated peptide antibodies (anti-
CCP antibodies) has more than 90% specificity.11 
Rheumatoid Arthritis can start at any age, usually in the fourth decade of 
life. It is more commonly seen in females with female to male ratio – 3:1 and 
this excess is greater in young people and the age related incidence is almost  
equal in elderly people.12 
Rheumatoid Arthritis is prevalent world wide involving all ethnic groups 
with 0.3-1% prevalence. In India the prevalence is around0.65-0.75%.13 and 
in rural population it is 0.7% 14 
There are several extra-articular manifestations (EAM) in Rheumatoid 
Arthritis, one among them being renal involvement15. Renal impairment is 
highly prevalent as denoted by reduced glomerular filtration and 
tubularfunction161718. Many morphological findings in the kidneys have 
beendocumented161920 and renal disease is thought to be a frequent cause of 
death in Rheumatoid Arthritis 21.So, identifying those at risk of developing 
clinical nephropathy is important and for this sensitive measure of renal 
function should be available.  
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Protein loss from glomerulus in Rheumatoid Arthritis is implicated to 
complications caused by the disease in its advance stages like 
• direct injury to kidney caused by the disease, or  
• the side effects causing nephrotoxic drugs,or  
• both. 
Subclinical renal dysfunction is also common in Rheumatoid Arthritis, 
and most of these can’t be detected by routine lab tests like urine total protein 
assays or Albustix.2223 
Microalbuminuria (MA) is found to be a sensitive indicator of 
subclinical renal dysfunction..American Diabetes Association (ADA) defines 
microalbuminuria as urinary albumin excretion of 30–299 mg/ 24 h or 
albumin/ creatinine ratio of 30-299µg albumin/mg creatinine24. 
The “Gold Standard” for estimating urine albumin quantitatively and 
defining Microalbuminuria, is 24-hour urine sample collection. But, it is 
cumbersome and error- prone .2526Currently, the National Kidney Foundation    
recommends detection of microalbuminuria with spot Urine Albumin-
Creatinine Ratio (UACR) obtained under standardized conditions. Albumin-
Creatinine Ratio (ACR) is more convenient for patients and less likely to get 
false results due to improper methods used for collecting the urine sample.27 
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Various methods are being used for measuring ACR. They are: 
 Dipstick method. 
 Semi quantitative methods 
 Chemical precipitation(Sulphosalicylic acid trichloroacetic 
acid) 
 Immune precipitation (Micral test) 
 Photometric method 
  Nephelometric method. 
  Sensitive quantitative methods 
 Radioimmuno assay(gold standard) 
 Cellulose acetate agarose gel electrophoresis. 
 
Calculations (formulae): Urine Albumin:creatinine ratio(UACR) 
 It is ratio of urinary albumin to urinary creatinine , usually expressed as 
milligram of albumin excreted per gram of urinary creatinine. 
 
ACR (mg/g) = (	/)
(	/)
x 1000. 
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For many diseases including diabetes ,microalbuminuria is considered 
to be a significant marker of mortality28.Numerous  studies have shown  
association of microalbuminuria with increased risk for renal and 
cardiovascular mortality and morbidity in diabetes, hypertension , patient 
swith acute myocardial infarction and also in general population. Rheumatoid 
Arthritis patients with microalbuminuria were seen to have increased 
mortality with hazard ratio 2.77 when compared to those with normal clinical 
renal findings.28 
Earlier presence of microalbuminuria may be an indicator of risk for 
renal dysfunction.Increased excretion of albumin in urine suggests not only 
glomerular disease, but also the disease activity and inflammatory state.29 
    Microalbuminuria is more prevalent in Rheumatoid Arthritis patients 
than in general population. For exact assessment of subclinical renal 
dysfunction in Rheumatoid Arthritis patients, estimation of microalbuminuria 
is a reliable method. Patients with Rheumatoid Arthritis are at increased risk 
of developing renal complications and presence of proteinuria increases the 
mortality rate. Therefore in clinical practice, it is essential to have a sensitive 
method for measuring renal dysfunction 303132 
With the invent of assays sensitive and specific for urinary albumin 
,earlier detection of glomerular abnormalities has been made possible in 
patients without any renal involvement clinically129 
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Few of the parameters which were used for observing the disease 
activity in Rheumatoid Arthritis were ESR,CRP, etc. But there is individual 
variation in the presentation and course of RA. The clinical features of RA 
varies widely with complaints such as fatigue , weakness , arthralgias , joint 
stiffness, joint swelling , functional impairment of joints involved , low grade 
fever , weight loss and so on .  
Since this disease has varied expression, a group of certain variables is 
being used for evaluating the severity of the disease,joint destruction and 
disabilities3334. The disease activity score (DAS) was developed, which is a 
more valid variable for measuring the Rheumatoid Arthritis disease activity 
when compared with the various existing disease activity variables3536. 
DAS28 is more valuable in doing researches. 
 
Advantages of DAS 
(i) It has a continuous scale with a Gaussian distribution. It indicates 
the extent of underlying inflammation. DAS has more information when 
compared to single measures alone, its values can be interpreted 
clinically, and  is very sensitive to small effects. 
(ii) It is also a component in EULAR response criteria which signifies a 
clinically important target of disease modifying anti-rheumatic drug 
(DMARD) therapy. 
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(iii) Since a measure with an absolute value is being incorporated, treatment 
responses in clinical trials can be meaningfully compared, especially in 
case of comparative or non-superiority trials. 
(iv) It will be helpful in future trials of highly effective DMARDs. 
(v) results of the trials conducted can be analysed as a clinically significant 
result that is applicable to a clinical set up. The disease activity score 
(DAS) can be helpful in monitoring the suppression of rheumatoid 
arthritis disease activity with DMARDs or “biologicals”. 
(vi) Measures like “time-to-low-disease activity” or “time-in-low-disease 
activity” possibly will become valid as endpoints in clinical trials as soon 
as even more efficient new drugs become available in the future; these 
potential endpoints can already be calculated by means of the DAS and 
DAS28. 
Problems in calculation and interpretation are the major disadvantages of 
indices such as disease activity score (DAS).37 
Since decreased and non-graded joint counts are employed in DAS28, it 
is easier to complete than DAS. The DAS28 has a continuous scale ranging 
between 0and 9.4, and it frequently exhibits a Gaussian distribution in 
patients with Rheumatoid Arthritis. Direct comparison of DAS andDAS28 
values is not possible; however there exists a formula for converting DAS28 
into DAS values.38 
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As per the ARA criteria, a disease activity score (DAS)< 2.6 denotes 
remission.39This means that almost all Rheumatoid Arthritis patients in 
remission have a DAS28 < 2.6, however not all patients with DAS28 < 2.6 
are in remission. In a patient,a change of 1.2 (i.e., 2 times the measurement 
error) of the DAS28is thought to besignificant.38 
DAS28 are measures with absolute values, they can be utilized to find 
out and assess the status and course of disease activity in individual RA 
patients, in distinction with relative measures such as the ACR improvement 
criteria.4041 
The validation profile of DAS28 (ESR) and DAS28 (CRP) was alike. 
This suggests that both measures are helpful in assessing disease activity in 
patients with Rheumatoid Arthritis42. DAS28-CRP may possibly undervalue 
disease activity in Rheumatoid Arthritis patients, when compared with 
DAS28-ESR for both sexes and various age groups4344. There aren’t many 
studies conducted to assess the relationship between microalbuminuria and 
Rheumatoid Arthritis disease activity according to DAS28 score, although 
DAS28has been widely validated and are frequently used in RA clinical 
trials. 
The present study is conducted to estimate the prevalence of 
microalbuminuria in Rheumatoid Arthritis and its association with disease 
activity using Disease Activity Score 28(DAS28-ESR). 
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REVIEW  OF  LITERATURE 
 
The aetiology of Rheumatoid Arthritis is not known. It involves 
interaction among genotype, various environmental triggers, and chance. 
MacGregor AJ et al45 implicated genetic factors in Rheumatoid 
Arthritis in their twin studies in 2000. They found the concordance rates to be 
15 to 30% and 5%among monozygotic and dizygotic twins respectively. 
Wellcome Trust Case Control Consortium46, in 2007, conducted a 
Genome-wide association study of 14,000 cases of seven common diseases 
and 3,000 shared controls. The study showed that immune regulatory factors 
trigger the disease. 
Stastny P.47 found that HLA-DR4is associated with Rheumatoid 
Arthritis and also that the relative risk of Rheumatoid Arthritis in patients 
with this allele is around 4-5. 
Gregersen PK et al48 in 1987, found that only some of the subtypes of 
HLA-DR4 (HLA-DW4 and HLA-DW14) are associated with Rheumatoid 
Arthritis; and Auger I et al 49 in 1997observed that shared epitope on the 
HLA molecule (HLADRB1) has high association with RA .Aghighi Y et al50 
in 2007 proposed and found that patients with EBV infection have increased 
risk of developing JRA. Association of Rheumatoid Arthritis with infectious 
agents like Epstein - Barr virus, Cytomegalo Virus, proteus species, and 
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Escherichia coli and their products(e.g., heat-shock proteins) may be 
attributed to some form of molecular mimicry though exact mechanism is 
unknown.51 
Rheumatoid factor (RF) is a high-affinity autoantibody against the Fc 
part of immunoglobulin and its induction is triggered by immune complexes 
during infection. For a long time, Rheumatoid Factor was used as diagnostic 
marker of Rheumatoid Arthritis and its role in the pathogenesis of the disease 
has already been established. 
In a study conducted by Wegner N et al52in 2010, with the use of 
immunoblotting technique they found that there appears to be an association 
of periodontal disease with RA: Porphyromonas gingivaliswhich expresses 
PAD (peptidyl arginine deaminases), is seen to be abletopromote 
citrullination of mammalian proteins. Deleting the bacterial PAD gene 
resulted in complete discontinuation of protein citrullination .Inactivating 
arginine gingipains resulted in decreased citrullination but not lysine 
gingipains. 
It is now found that gut micro flora plays a role in the development of 
autoimmunity in articular models. There are specific, potentially traceable 
clinical bacterial signatures that are emerging in association with 
autoantibody positive Rheumatoid Arthritis.Scher JU et al53advocatedthat 
production of anti-citrullinated peptide antibodies (ACPA) may have 
association with greater populations of Prevotellaceae in both oral and 
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intestinal micro flora. They proposed that this altered micro flora may be 
responsible for the development of auto inflammatory disease in some 
predisposed individuals, by many mechanisms including cyclic citrullinated 
peptide generation or activating Th17cell in the intestinal mucosa. They also 
came to a conclusion that additional investigations would be helpful in 
finding out the oral and intestinal microbial flora as potential triggers for 
autoimmunity and clinical Rheumatoid Arthritis. It has been accepted that 
risk of Rheumatoid Arthritis is more in women than in men. There is a link 
between the hypothalamic–pituitary–adrenal axis and production of cytokine. 
In a study done by Capellino S et al54, in 2010,it was observed that around 
the onset of Rheumatoid Arthritis ,local catecholamine-producing cells starts 
replacing sympathetic nerve fibres. These locally produced catecholamines 
when modulated have strong anti-inflammatory effects in vivo and in vitro. 
Severe life threatening morbidity associated with rheumatoid arthritis is being 
supported by the above given data. 
Rheumatoid factor (RF) is an IgM antibody against the Fc segment of 
IgG antibody seen in about 70% of Rheumatoid Arthritis patients.55 There is 
proof suggesting involvement of rheumatoid factor in the pathogenesis of 
Rheumatoid Arthritis56. Silman AJ and Hockberg57, in their study found that 
enhanced presentation of immune-complexed agents, cross-linkage and 
stabilization of low-avidity IgG antibodies, and cryoprecipitation are the 
mechanisms in pathogenesis of Rheumatoid Arthritis. Rantapaa-Dahlqvist S 
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et al56,observed that autoantibodies like Rheumatoid Factor and anti-cyclic 
citrullinated peptide antibodies (anti-CCP antibodies), are frequently (not 
always) seen in patients before they develop arthritis (i.e, in the pre-articular 
phase of Rheumatoid Arthritis) and in some series ,levels of auto antibodies 
have elevated. They also observed existence of epitope spreading along with 
the disease onset and its progress .Rheumatoid Factor does not have 
diagnostic specificity in Rheumatoid Arthritis. It can be seen in a wide variety 
of conditions other than Rheumatoid Arthritis like bacterial infection, liver 
disease, lymphoproliferative disorders and other autoimmune disorders. 
The occurrence of Rheumatoid Factor(not anti-CCP)in Rheumatoid 
Arthritis is related with extra articular manifestations and a milder form of the 
disease is seen when Rheumatoid Factor is not present.585 
Turesson C et al59 conducted a study on 35 consecutive patients with 
severe extra-articular manifestations (EAM) and comparing them with 70 
patients having Rheumatoid Arthritis without extra articular manifestations, 
individually matched for age, sex and duration of the disease, served as 
controls. Rheumatoid Factor was positive in94% v 71% of patients and 
control population, respectively (p = 0.006), and levels of Rheumatoid Factor 
were more in patients with extra articular manifestations (median interquartile 
range (IQR) 245 IU/ml (94-604) v73 IU/ml (not detected-165); p = 0.001). 
They came to a conclusion that in Rheumatoid Arthritis patients, both 
Rheumatoid Factor and anti-CCPs are associated with severe extra articular 
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manifestations though much stronger association exists for Rheumatoid 
Factor. This is indicative of their function in the pathogenesis of extra 
articular manifestations.  
Extra articular manifestations are commonly seen in about 17.8%–50.1% 
of patients with Rheumatoid Arthritis and are related with poorer outcomes 
than those without extra articular manifestations. They have higher morbidity 
and mortality, and poor functional status.6263646566 
Calguneri M et al62 from Turkey observed in their study on 526 patients 
that 202 patients had extra articular manifestations (with a frequency of 
38.4%), most common among them being rheumatoid nodules 
(18.1%).Sjogrens syndrome symptoms, lung findings, livedo reticularis, 
Raynaud's phenomenon, carpal tunnel syndrome, vasculitis, amyloidosis, and 
Felty syndrome were present in 11.4%, 4.8%, 4.8%,3%,  2.8%, 1.3%, 1.1%, 
and 0.3%of the patients, respectively. In general, patients with positive 
Rheumatoid Factor presents with extra articular manifestations and 
rheumatoid nodule is more commonly than those in whom Rheumatoid 
Factor is negative. They also observed that rheumatoid nodules are more 
frequently seen in males. 
Myasoedova etal65 in 2011 gathered together from the available medical 
records, information on incident extra articular manifestations in Rheumatoid 
Arthritis patients among Olmsted County residents who first met the 
1987ACR(American College of Rheumatology) criteria for Rheumatoid 
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Arthritis between January 1, 1995, and December 31, 2007. They were 
followed until demise, relocation from Olmsted County, or December 31, 
2008. A predefined criteria was used to classify extra articular manifestations 
and compared to the corresponding 1985-1994 inception Rheumatoid 
Arthritis cohort (n = 147). They found that the 10-year cumulative incidence 
of any extra articular manifestations (50.1%) and severe extra articular 
manifestations (6.7%) in the 1995-2007 cohort was similar to the 1985-1994 
cohort (46.2% and9.7%, respectively). The cumulative vasculitic incidence 
over the past ten years was significant but not other features of extra articular 
manifestations, was relatively lower in the 1995-2007 cohort (0.6%) when 
comparing with the 1985-1994 cohort (3.6%). Positive RF, 
erosive/destructive joints, and use of drugs like DMARDs and systemic 
steroids had significant association with extra articular manifestations in the 
1995-2007 cohort. 
The 1995-2007 cohort showed increased risk of mortality in association 
with extra articular manifestations (HR 2.1, 95% CI 1.2, 3.7). The reduction 
in mortality following extra articular manifestations in the 1995-2007 cohort 
opposed to the1985-1994 cohort did not attain statistical significance (HR 
0.6, 95% CI 0.3, 1.2, p =0.16). They came to a conclusion that presence of 
extra articular manifestations in Rheumatoid Arthritis patients is frequently 
associated with increased mortality. Recently, the incidence of vasculitis 
seems to be declining. 
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Turesson C et al66 in 2006 studied the cardiovascular risk among 
Rheumatoid Arthritis patients with severe extra articular manifestations and a 
relation between them. They found that this relation is not because of any 
differences in age, sex, smoking habits, presence of Rheumatoid Factor or 
erosive changes in the joints and arrived at a conclusion that extra articular 
manifestations remain a main feature in determining the risk of 
cardiovascular disease in patients with rheumatoid arthritis. 
Among the extra articular manifestations, most commonly occurring is 
rheumatoid nodules present in about 20% of patients with RA. They are 
usually seen at sites which are subjected to constant pressure like extensor 
surfaces of forearm and posterior surface of the tendoachilles. Definite 
diagnosis of rheumatoid nodules is by biopsy, which on histopathological 
examination will demonstrate 3 zones – (1)outer zone with granulation tissue, 
(2)middle zone having pallisading macrophages, and (3)central zone with 
necrotic material.67 
The disease process also affects several other systems. 
Numerous morphological changes have been demonstrated in the 
kidneys in patients with RA161920 and involvement of the kidneys is thought to 
be a common reason for death in Rheumatoid Arthritis.6869 
Boers M et al16 in their autopsy based study, noticed that patients with 
Rheumatoid Arthritis showed certain morphological changes in the kidneys 
like sclerosis of the kidney(90%), rheumatoid vasculitis (14%) with renal 
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involvement in 8%,amyloidosis (11%), membranous nephropathy(8%), and 
focal glomerulonephritis(8%). They recommended that these changes could 
be due to both rheumatoid and non-rheumatoid disease as suggested by 
clinical data. 
Ramirez G et al19conducted an autopsy based study on 76 patients 
having rheumatoid arthritis, performed at the University of Utah and Salt 
Lake Veterans Administration Medical Center. 
The most common among the renal changes were interstitial 
fibrosis(46%) and arteriolar wall thickening without significant evidence of 
hypertension(54%).Only 7% had renal amyloidosis. Although not clinically 
relevant, 9% of rheumatoid arthritis patients were detected to have creatinine 
levels above 2mg/dl. Furthermore, it was seen that azotemia was not a 
common cause of mortality in these patients. 
Sellars L et al20did a study where they took renal biopsies from 30 
patients having Rheumatoid Arthritis and analysed clinical evidence of renal 
disease; biopsy was taken only from those who showed normal intravenous 
pyelogram, thereby excluding patients with papillary necrosis and chronic 
pyelonephritis. The biopsy materials were examined under light, electron and 
immunofluorescence microscopy. Out of the 30 patients,there were 13 cases 
showing  mesangial change, 9 cases of membranous glomerulopathy, 4 cases 
of tubulointerstitial nephritis, 2 cases of focal glomerular sclerosis, 1 case of 
amyloidosis and 1case of diffuse glomerulonephritis frequently with 
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epithelial crescent formations. All those having membraneous 
glomerulopathy and 6 among the 13 patients showing mesangial changes, had 
been given either gold or penicillamine. There wasn’t any evidence 
suggestive of “glomerulitis" or systemic vasculitis associated with RA. 
Laakso et al21carried out a study on 1000 Rheumatoid Arthritis 
patients(500 males and 500 females) aged ≥ 40 years along with an age and 
sex matched control group, and followed them up for 10 years. A higher 
mortality rate was observed among Rheumatoid Arthritis patients 
(irrespective of their gender), when comparing with the control population. 
This was mainly due to increased death from infections and diseases affecting 
the heart and kidneys. In the 10 year follow up period , 31 patients having 
Rheumatoid Arthritis (12 male and 19 female) and one male patient among 
the control group died from amyloidosis,and 42 Rheumatoid Arthritis patients 
(19 male and 23 female) and one male patient among the control group died 
due to renal disorders. 
The major reasons for mortality due to renal diseases were infections 
and chronic glomerulo nephritis. 
Boers et al22 and Bird et al23suggested that subclinical involvement of 
the kidneys is usual in Rheumatoid Arthritis and for detection of protein 
excreted in urine, albustix and other simple tests may not have the necessary 
sensitivity. In order to identify the presence of microalbuminuria at an earlier 
stage, there need to more sensitive tests available for use. 
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Molitch et al24 from the American Diabetes Association(ADA) in 2004 
formed a definition for Microalbuminuria as urinary albumin excretion of  
30–299 mg/ 24 h or albumin/creatinine ratio of 30-299 µg albumin/mg 
creatinine. 
Wiseman MJ and Viberti G70 in 1985 interpreted the mechanism by 
which microalbuminuria is present in diabetic nephropathy. They suggested 
that permeability of the glomerulus to albumin depends on the presence of 
negative endothelial charge and also size selectivity. They found that the 
negative charge present on the glomerular basement membrane is due to a 
constant glycoprotein and this is responsible for the controlled passage of 
anionic proteins across the membrane. They also found that presence of 
microproteinuria signifies a defect at the glomerular level, and albumin and 
IgG form the major constituents. Microproteinuria is seen to be related with 
poor control of blood sugar levels and also mild increase of arterial pressure. 
This may be due to the hemodynamic changes occurring in the glomerulus 
and loss of endothelial charge selectivity, and it was seen that 
microproteinuria can be reversed by correcting hyperglycemia and controlling 
blood pressure levels. A continuous fall in GFR would occur once a positive 
dipstic test (i.e. total urinary protein excretion more than0.5 g/day) is 
observed and patient becomes hypertensive. When the GFR becomes as low 
as 20 ml/min/1.73 m2, comparatively more IgG than albumin will be filtered 
resulting in a low selectivity proteinuria. This is consistent with changes in 
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the size selectivity features of the glomerular filter. They observed that 
controlling blood sugar levels have no effect on GFR but controlling blood 
pressure and following a low protein diet can slow down GFR, most likely by 
modifying the continuous hemodynamic disturbances occurring in the 
remaining glomeruli. They also found that in view of the fact that 
microalbuminuria is reversible at an early stage, it gives the possibility of 
achieving prevention of the later irreversible stage of end stage renal failure. 
Gosling P et al71 in 1989 observed loss of charge selectivity of the 
glomerulus in those with microalbuminuria irrespective of whether they are 
diabetic or not. 
Other likely mechanisms of microalbuminuria include the following: 
Stender S and Hjelms E.72 in 1987 proposed the systemic transvascular 
albumin leakage: transcapillary escape rate of albumin (TERalb) is defined as 
the fraction of the intravascular mass of albumin (IVMA) going through the 
vascular bed per unit time. The TERalb is an overall measure of the 
permeability of the vascular bed in vivo to various macromolecules .Presence 
of microalbuminuria suggests systemic transvascular leakiness for albumin, 
and also allowing increased lipid insudation into the wall of large vessels; 
hence microalbuminuria may be related to atherogenesis. 
Lindberg G et al73 in 1992 described that sialic acid has an effect on 
many haematological factors, transvascular permeability and lipid 
accumulation in the arterial wall. Studies revealed that in those without 
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diabetes, an increased serum sialic acid levels in association with increased 
albuminuria is predictive of atherosclerotic vascular disorder. 
Clausen P et al74 in 2001 in their study observed that mild increase in 
excretion of urine albumin is found to be related with defective conduit 
arterial dilatory capacity in clinically healthy study population. This defect 
could be the result of decreased dilatory response to endogenous or 
exogenous nitric oxide and it may add to the cardiovascular risk in those with 
elevated urine albumin. 
Lee P et al75conducted a study in 1993 which revealed increased levels 
of certain prothrombotic(fibrinogen and factor VII C) and anti thrombotic 
factors(protein C, protein S and antithrombinIII) in type 1 diabetes subjects 
with microalbuminuria, and also in those having hypertension. These factors 
were thought out to be a good indicator of endothelial dysfunction. 
Kuusisto J et al76 in 1995 observed the role of insulin in smooth muscle 
cell proliferation, stimulation of  LDL binding muscle cells, fibroblasts and 
monocytes, and in vitro cholesterol synthesis in monocytes and found out that 
patients with elevated insulin levels and microalbuminuria have high risk of 
cardiovascular disease. 
Svenson KL et al 77 in 1988 found a comparatively better insulin 
response and impaired glucose handling in patients with active Rheumatoid 
Arthritis than the healthy control population. HällgrenR and Berne C78 in 
1983 and Dessein PH et al79 in 2002 saw that administration of certain drugs 
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having anti-inflamatory action like corticosteroids and DMARDs resulted in a 
temporary decline in insulin resistance.777879 
The increased risk for developing cardiovascular and cerebrovascular 
disease in patients having micoalbuminuria may be attributed to a certain 
extent to homocysteinemia, which is an atherogenic risk factor. 24 
Bakris GL80 in his journal on clinical hypertension published in 2001 
suggested that the earliest clinical evidence of diabetic nephropathy is 
microalbuminuria. He also observed various studies suggesting 
microalbuminuria as a major cardiovascular risk factor. Presence of 
microalbuminuria in patients with type 2 diabetes or essential hypertension 
increases the risk of early death from cardiovascular diseases. 
Microalbuminuria also denotes atherosclerosis and abnormal permeability of 
the vessels. Microalbuminuria in non-diabetic patients with essential 
hypertension is shown to have an association with high blood pressure levels, 
hypercholesterolemia, and decreased serum HDL (high-density 
lipoprotein)cholesterol. Gathering all these information,a concept was 
developed. It suggested that “occurrence of microalbuminuria is the kidney's 
warning to the physician/patient of the increased risk for developing 
cardiovascular diseases and that there is a defect with the vasculature”. By 
controlling blood pressure levels, reduction of microalbuminuria can be 
achieved, and also prevent the development of overt proteinuria. 
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In the two studies conducted in the early 1980s by Parving HH et al 81 
in Denmark and Viberti GC etal82 in London, they mentioned the 
significance of MA. They independently suggested that an increased level of 
microalbuminuria is a strong predictor of progression to diabetic kidney 
disease. They observed that these levels of AER (Albumin Excretion Rate) 
can be reversed, and intervention at the appropriate time may prevent diabetic 
nephropathy. Microalbuminuria predicts the progression to overt diabetic 
renal disease and kidney failure. 
Mogensen CE83 in 1984 noticed clinically detectable increased urinary 
protein excretion and greater mortality in type 2 diabetes patients with 
micoalbuminuria. There are a number of studies suggesting microalbuminuria 
as a predictor of development of nephropathy and also higher cardiovascular 
risk and overall mortality, in patients with diabetes mellitus.  
Allawi J et al84 in 1990 observed the relation between persistent 
microalbuminuria and presence of dyslipidemia, hypertension and obesity, in 
type 2 diabetes. 
The ADA in 1998, considered to include presence of MicroAlbuminuria 
as a risk factor for ischemic heart disease in patients with DM.85 
Jensen JS et al 86in 1995 suggested that positive microalbuminuria is a 
risk factor for atherosclerosis. 
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A high morbidity and mortality due to atherosclerotic cardiovascular 
disease were seen in those having a mildly increased UAER(urinary albumin 
excretion rate), known as microalbuminuria. Hence, the relationship between 
microalbuminuria and the well-known risk factors for atherosclerosis was 
reviewed in clinically healthy population. Among the healthy 40-65 year-old 
participants with microalbuminuria, who were examined within the first 21 
months of The Copenhagen City Heart Study, 28 were chosen for the study. 
The control group selected for the study included an age- and sex-matched 
group of 60randomly chosen subjects with normal urinary albumin excretion. 
Microalbuminuria is thought to be an important predictor of progression to 
overt diabetic renal disease 82 and hence it was well accepted as a risk factor 
for the development of cardiovascular disease (CVD). 
Microalbuminuria usually shows an association with increased levels of 
many inflammatory factors whether or not hypertension or diabetes is present 
.Barzilay JI et al87 in2004 suggested that inflammation preceded the onset of 
microalbuminuria. They observed that levels of inflammatory markers, age 
and higher levels of systolic blood pressure show a relationship with 
microalbuminuria in elderly population, either with or without hypertension 
or diabetes. Since these are risk factors for coronary artery disease (CAD), 
these investigations find the relationship between microalbuminuria and 
CHD. 
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Diercks GF et al 88performed a study on 7579 non-diabetic subjects 
aged between 28 to 75 years chosen from a population based cohort and 
observed that there is an independent association between microalbuminuria 
and ischemic ECG abnormalities. This suggested that microalbuminuria has 
an added significance when compared to the usual risk indicators in 
predicting cardiovascular disease in non-diabetics. They proposed that 
evaluating for the presence of microalbuminuria would aid in early 
recognition of those at high risk for coronary heart disease. 
Festa A et al89proposed that microalbuminuria represents a widespread 
damage of the vessels and that it has a strong association with inflammation 
which is seen underlying every stage of atherosclerosis. 
Neil A et al90 in 1993 performed a study on 249patients with NIDDM 
(Non Insulin Dependent Diabetes Mellitus). The results obtained from this 
population-based cohort confirmed that microalbuminuria is a good predictor 
of mortality risk in patients with NIDDM. Comparing with the prospective 
studies on conventional risk factors for cardiovascular disease in patients with 
NIDDM, there was evidence suggesting microalbuminuria as an independent 
predictor of increased mortality. 
A Study by Agarwal et al91 in 1996 showed increased prevalence of 
microalbuminuria in patients with hypertension, especially among those in 
whom blood pressure characteristics are related with increased cardiovascular 
risk, such as salt sensitivity and an atypical diurnal variation in blood 
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pressure. They came to a conclusion that presence of microalbuminuria 
allows early identification of development of renal and cardiovascular 
complications in hypertensive patients. 
There are several studies showing the association between 
microalbuminuria and other atherogenic risk factors like hypertension, 
hyperlipidemia, and smoking in the general population. Damsgaard EM et 
al92 in their study conducted in 1990, found out that microalbuminuria is an 
important predictor of high mortality among elderly individuals. 
Microalbuminuria is seen to be present in the earlier stages of acute 
myocardial infarction and is thought of as an independent predictor of early 
death in this disease condition. It was also seen that microalbuminuria is 
proportional to infarct size. 
Gosling et al93 in 1991recommended that early increase in urinary 
albumin concentration is valuable in differentiating a myocardial infarct from 
an angina. A higher level of excretion of urinary protein seems to be an early 
and proportionate response to myocardial infarction.  
Roine I94 in 1993 established that microalbuminuria is 94% specific in 
differentiating bacterial from aseptic meningitis. He observed that 
microalbuminuria is a potential acute phase reactant for the early assessment 
of severity of bacterial meningitis, and that its estimation is easy and involves 
non invasive procedure. 
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Shearman et al95observed peaking of micoalbuminuria in cases with 
acute pancreatitis 36 hours following admission. They also observed 
development of serious complications in association with higher levels of 
microalbuminuria. 
Pallister et al 96observed in their study that in trauma patients 8 hours 
after admission, levels of microalbuminuria is a good predictor for 
development of ARDS (positive predictive value - 85% ; negative predictive 
value - 95%). 
Mykkanen L et al97observed that microalbuminuria is associated with 
thickness of carotid artery intima-media, suggesting that it may be an 
indicator of early atherosclerotic changes in the carotid artery, and points 
towards a possible relationship between microalbuminuria and mechanism of 
atherothrombotic stroke. 
Mahmud N et al98 in 1994 came to the conclusion that 
microalbuminuria is most likely the result of an acute phase reaction and it 
serves as an easy, quick to perform, and economical test, capable of 
monitoring disease activity as well as treatment response in inflammatory 
bowel disease. 
Hickey NC et al99 in 1990 observed in their study that 
microalbuminuria, which was formerly demonstrated to represent vascular 
permeability, was seen to increase considerably following exercise in 
claudicants. 
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Tagle et al107 in 2003 suggested microalbuminuria as a strong predictor 
of cardiovascular morbidity and mortality, clinical nephropathy, and 
development of kidney disease in high-risk individuals. Screening is advised 
for patients with type 2 diabetes, elderly patients having type 1 diabetes, and 
elderly patients with stage 2 hypertension or higher(i.e.,≥ 160/100 mm Hg). 
There are numerous pathways linking microalbuminuria and vascular disease. 
Several factors like resistance to insulin, central obesity, reduced levels of 
HDL cholesterol, increased triglyceride levels, systolic hypertension, absence 
of fall in blood pressure levels during night time, salt sensitivity, endothelial 
dysfunction, hypercoagulability, defective fibrinolysis and dysfunctioning of 
the kidneys are seen to be associated with microalbuminuria. This gives 
sufficient evidence supporting the role of microalbuminuria in predicting 
vascular disease among high risk individuals. Therefore, a regular screening 
for detecting the presence of microalbuminuria would be helpful in 
recognising those patients at increased risk of developing cardiovascular 
disease and they require early intervention, intensive treatment, and close 
follow up. 
Nakamura M et al103 in 2004 observed a significant association 
between low-grade inflammation as reflected by high sensitivity CRP levels 
and microalbuminuria, suggesting that microalbuminuria may be a useful 
indicator of systemic low-grade inflammation and a well recognised risk 
factor for cardiovascular disease among seemingly healthy population. 
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Pedersen LM et al100 (1995) conducted a study on 65 rheumatoid 
arthritis patients attending 2 rheumatology clinics and they were compared 
with 51 age and sex matched controls. Their study showed that 27.7% of 
rheumatoid arthritis patients and 7.8% of the controls were detected to have 
microalbuminuria (with urine albumin to creatinine ratio ranging between 3-
30 mg/mmol in either or both urine specimens collected).There was 
significant association between urine albumin creatinine ratio and CRP, and 
disease duration. It was also observed that therapy involving the use of gold 
and pencillamine had increased risk of developing microalbuminuria. No 
significant association was found between ESR (erythrocyte sedimentation 
rate) and MA. 
In a study by Bhatt et al101, 30% of rheumatoid arthritis patients were 
detected to have microalbuminuria, especially those in whom the disease was 
severe and was present for a long duration. 
Saito M et al102 in 1993 studied the relevance of microalbuminuria in 
rheumatoid arthritis. The study was performed on 138 rheumatoid arthritis 
patients not having microalbuminuria. Estimation of microalbuminuria was 
done by double antibody radioimmunoassay (RIA)method in the ambulatory 
urine sample. At the same time, urinary (U) beta 2-microglobulin (BMG) and 
N-acetyl-beta-D-glucosaminidase (NAG) were also estimated. U-Alb indices 
(MA/U-creatinine ratio) in rheumatoid arthritis, osteoarthropathy (OA), and 
normal controls were 25.7 ± 38.2,11.4  ±  11.5 and 7.7 ±  3.5  respectively. It 
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was seen to be significantly higher in rheumatoid arthritis patients when 
compared with the values in patients having osteoarthropathy and in normal 
controls. They observed higher values of U-Alb index in rheumatoid arthritis 
patients receiving lovenzarit disodium and gold sodium thiomalate (GST).It 
was found that U-Alb indices were not associated with the clinical findings, 
U-BMG indices and U-NAG indices in patients with Rheumatoid Arthritis. 
U-Alb index, U-BMG index and U-NAG index were sequentially calculated 
in a rheumatoid arthritis patient who had massive MA while on treatment 
with GST, and it was observed that first U-Alb index increased, then U-NAG 
index and ultimately there was also an increase in U-BMG index. This shows 
that U-Alb indices are increased in rheumatoid arthritis patients without 
macroalbuminuria, and serial estimation of microalbuminuria in patients 
having rheumatoid arthritis, particularly those on DMARDs will be helpful in 
detecting subclinical glomerular insult. 
Nordin et al104 in 1996 performed a study on 65 patients having RA 
comparing them with 51 controls matched by age and sex. There was 
significant elevation of microalbuminuria in rheumatoid arthritis patients 
(27.7%) when compared with the control population (7.8%).The median 
disease duration was significantly higher in patients having microalbuminuria 
(11.2 v 7.8 years; p < 0.001). CRP was identified as an important indicator of 
disease activity. They also found a significant correlation to therapy with gold 
and pencillamine. In conclusion, microalbuminuria measured by 
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immunochemical methods is a simple sensitive test for identifying subclinical 
damage to the kidney and could be a sensitive marker of disease activity in 
rheumatoid arthritis. Microalbuminuria can be utilised for monitoring early 
subclinical dysfunction of the kidneys and damage caused to the kidneys by 
drugs, in patients having rheumatoid arthritis.  
Monica V et al105 in 2013 observed that the increased prevalence of 
microalbuminuria is associated with Rheumatoid Arthritis disease activity 
based on ESR and CRP. They also found a correlation between MA and 
increase in disease duration and number of joints affected. Thus, they arrived 
at a conclusion that microalbuminuria appears to represent the disease activity 
in rheumatoid arthritis.  
In 1963, Keen and Chlouveraskis106detailed the first specific 
radioimmunoassay (RIA) for urine albumin. Radioimmunoassay for 
microalbuminuria is the “gold standard” for the measuring urine albumin. 
This method involves a double antibody technique in which albumin present 
in the test sample binds to specific antibody sites competing with a fixed 
amount of 125I labelled albumin. Separation of bound and free forms of 
albumin is achieved by adding a second antibody immunoabsorbent and 
thereafter by centrifugation and decanting. C counter is used for measuring 
the radioactivity in the pellet. 
 
 
 33 
 
Concentration of albumin in the sample is inversely proportional to 
radioactivity. Radioimmunoassay shows a sensitivity of 0.3mg/l. Rheumatoid 
arthritis is a chronic inflammatory disease with varied disease expression. A 
range of variables(core-set variables) are being chosen for assessing the status 
and course of disease activity in rheumatoid arthritis, as well as disability and 
damage to the joint.108109 
Van Riel PL108 in 1992 recommended a set of core variables that can be 
helpful in assessing the status and course of Rheumatoid Arthritis disease 
activity, disability and joint damage. 
Felson DT et al109 in 1993 formed a committee on outcome measures in 
Rheumatoid Arthritis clinical trials . A core set of disease activity measures 
was suggested by them which included tender joint count, swollen joint 
count, patient’s assessment of pain, patients and physician’s global 
assessment of disease activity, patient’s assessment of physical function, and 
laboratory estimation of one acute-phase reactant. All these measures 
collectively illustrate the wide variety of improvement in Rheumatoid 
Arthritis, and all of them show at least a moderate sensitivity to change. Most 
of them are a good predictor of physical disability, radiographic changes, 
death and various other significant long term outcomes in Rheumatoid 
Arthritis. Other disease activity measures often used in clinical trials were not 
preferred for anyone of a number of reasons, including insensitivity to 
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alteration or repetition of information provided by one of the core variables 
(e.g., tender joint score and tender joint count). 
The committee also suggests specific ways of evaluating each outcome. 
Comparing with the various available disease activity variables 
separately, DAS offers a more suitable measure of disease activity in 
Rheumatoid Arthritis.3536 
Van der Heijde DM et al36in 1993, performed a prospective study on 
113 patients having early rheumatoid arthritis for a period of 3 years. Based 
on the clinical decision of six rheumatologists, they developed a disease 
activity score (DAS). In accordance with explicit rules, the study subjects 
were divided into two groups – those with high disease activity and those 
with low disease activity. A disease activity score (DAS) can be defined by 
means of a variety of statistical methods, including discriminant analysis and 
multiple regression analysis, and comprises of the variables, Ritchie articular 
index, number of swollen joints, ESR (erythrocyte sedimentation rate), and 
general health measured on a visual analogue scale. 
Prevoo et al110 in 1995 developed the modified DAS by recognized 
discriminate analyses and approved for criterion, co relational, and construct 
validity. 
Investigation as to how the duration of the disease influence the disease 
activity scores (DAS) composition was also carried out, and they did not 
observe any influence by disease duration. The Modified disease activity 
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score (DAS) which included 28-joint counts, is capable of differentiating 
between those with high and low disease activity (as determined by clinical 
opinion of rheumatologists). Since the modified DAS contains more inclusive 
joint counts, it is being considered as a valid disease activity score. The 
DAS28 (similar to the original DAS), comprises of a 28 tender joint count 
(range 0-28), a 28 swollen joint count (range 0-28), erythrocyte sedimentation 
rate (ESR), and an optional general health assessment on a visual analogue 
scale (range 0-100).Harikrishnan Aggarval et al111conducted a study based 
on the histopathology and functional status of the kidneys in 50 patients 
having rheumatoid arthritis. They observed that those with severe disease 
activity score (DAS) score usually showed involvement of the kidney. The 
study subjects were grouped into two based on the disease duration, with each 
group having 25 patients. Those patients with disease duration less than 5 
years were grouped under group 1, and more than 5 years under group 2. It 
was found that the mean DAS was greater in group 2. 
V Raveendran et al112 from SMS medical college and hospital, Jaipur, 
India, Performed a study about subclinical renal dysfunction in patients with 
rheumatoid arthritis, and observed significantly higher urine albumin 
excretion in patients having active disease (DAS28> 3.2) than those who 
were in remission (DAS28 < 2.6). 40 each of rheumatoid arthritis patients and 
healthy controls were taken for the study. 
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Microalbuminuria was significantly greater in rheumatoid arthritis patients 
(30%) than controls (5%).Also, rheumatoid arthritis patients with 
microalbuminuria were seen to have a significantly longer duration of the 
disease than those with normoalbuminuria. There was significant association 
between urine albumin excretion and erythrocyte sedimentation rate (ESR). 
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MATERIALS AND METHODS 
 
 
The study was conducted on 60 patients attending the rheumatology out 
patient department of Thanjavur Medical College, Thanjavur. Total study 
duration was 6 months from the date of ethical clearance. It was a cross 
sectional study. 
 
Inclusion criteria 
After clinical assessment and laboratory investigations, those patients 
aged above 12 years fulfilling the Modified ACR (American College of 
Rheumatology Association) criteria (1987) for Rheumatoid Arthritis were 
included in the study. 
 
Exclusion criteria 
Those patients having hypertension, diabetes mellitus, previous history 
suggestive of renal disease and paediatric age group less than 12 years were 
excluded from the study. 
 
 
Sample size, n=60 (n=4pq/l² p-prevalence in previous study, q=100-p, 
l=20% of p) 
An informed consent was obtained from all patients. 
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A detailed history was taken from all the patients and, age, sex, 
duration of RA, presence and duration of morning stiffness, chest symptoms, 
list of painful joints ,presence of other systemic disease and presence of extra-
articular manifestations of RA were recorded. 
 
Examination 
All joints were systematically examined for the presence of any 
tenderness, swelling, or deformity as well as the possible range of movements 
at these joints. Examination of the cardiovascular, respiratory, 
gastrointestinal, and nervous system was done. Patients were carefully 
observed for the presence of any extra articular manifestations and the 
findings were documented. 
Calculation of Disease activity score (DAS28) was done for all of them 
by means of DAS28calculator for ESR. 
 
Investigations 
 emphasis was given for the following investigations. 
 
Erythrocyte sedimentation rate 
ESR was measured using Westergren method. Venous blood was anti-
coagulated by trisodium citrate dehydrate in the ratio of 4:1 and well mixed 
by gentle, repeated inversion and used to fill a Westergren-Katz tube up to the 
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0(zero) mark. Subsequently, the tube was placed vertically in a rack, which is 
protected from direct sunlight, draught or vibration and incubated at room 
temperature for 1 hour (60 minutes). 
After one hour, the distance (in mm) from the bottom of the surface 
meniscus to the top of sedimenting red cells was noted and reported as the 
ESR value. This test was done within 2 hours of collecting blood samples. 
 
Rheumatoid factor (IgG) 
A quantitative assay was done employing a latex fixation lab kit. A 
value above 36 IU/ml was considered to be positive. 
 
C - reactive protein 
A quantitative assay was done employing ELISA technique. Values 
>6mg/l were taken as positive. 
 
Microalbuminuria(MA) 
Assessment of Urine albumin-creatinine ratio (U.ACR) from spot urine 
sample was done by radioimmunoassay. It gives a quantitative estimation of 
microalbuminuria. 
 
 
 
 40 
 
 
Routine investigations 
Haemoglobin, total leukocyte count, differential counts, blood urea 
,serum creatinine and blood sugar estimation were done. 
 
Disease Activity Scale score (DAS28) 
DAS28  = 0.56 x √(28TJC) + 0.28 x √(28SJC) +0.70 x Ln(ESR) + 0.014 x  
                 VAS 
 TJC-Total tender joints 
 SJC-Total swollen joints 
 ESR-Erythrocyte Sedimentation Rate in mm/hr 
 VAS-Visual Analogue Scale (patient puts a vertical mark on a 100 mm 
Scale corresponding to their general health or global disease activity. 
Measurement is taken from the left hand side using a ruler.) 
 
Interpretation: 
The DAS28 score provides a number on a scale from 0 to 10 representing 
the present RA disease activity. 
 Remission: DAS28 ≤ 2.6 
 Low Disease activity: 2.6 < DAS28 ≤ 3.2 
 Moderate Disease Activity: 3.2 < DAS28 ≤ 5.1 
 High Disease Activity:  DAS28 >5.1 38 
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Statistical methods   
         The significant association of clinical factors between patients with and 
without the presence of MA has been found out using Chi square test/Fischer 
Exact test. Odds ratio has been used to find the significant strength of 
relationship of factors in association with microalbuminuria. Student t test 
(two tailed, independent) has been used to find the significance of 
investigation parameters between the two patient groups. 
 
Statistical software 
SPSS 20.0 was used for data analysis and Microsoft word and excel 
have been used to generate graphs, tables etc. 
 
Ethical consideration 
Compilation of data required for the study was commenced only after 
getting clearance from the ethical committee. The privacy of the patient and 
the confidentiality of the clinical data were maintained during the study. A 
written consent was obtained from every patient before including him/her in 
the study. Those who did not consent were excluded from this study. No 
additional expenses were needed by the patients as part of this study. 
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OBSERVATIONS AND RESULTS 
 
  This study is a cross sectional study with case control comparison, 
done in Thanjavur Medical College, Thanjavur, between January 2016 and 
August 2016. 60 patients of RA diagnosed by means of modified ACR 
criteria (1987) were included in the study once they had satisfied the 
inclusion criteria. Patients with hypertension, diabetes mellitus or renal 
diseases, and individuals aged below 12 years were excluded from this study. 
 
Age and sex distribution  
The age group of the study population chosen ranged between 14 and 
81 years with a mean of 44.55 yrs (SD 13.767).Among the study population, 
the age of males ranging from 24 to 81 years showed a mean value of 46.529 
yrs (SD-13.005), and the age of females ranging from 14 to 72 years showed 
a mean of 43.767 yrs (SD-14.128). 55% of the study population belonged to 
the age group of 31 to 50 years; most of them (36.7%) belonged to the age 
group of 41 to 50 years. 
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Table 1.Age (years) of patients studied 
AGE (YEARS) NO: OF PATIENTS (%) 
‹ 30 9(15) 
31-40 11(18.3) 
41-50 22(36.7) 
51-60 12(20) 
› 60 6(10.0) 
Total 60(100) 
 
 
Figure 1.Age (years) of patients studied 
 
 
 
 
 
 
Out of the total 60 members in the study group, 43 were females 
(71.7%) and 17 were males (28.3%). 
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Table 2.Sex distribution of patients studied 
 
SEX NO: OF PATIENTS (%) 
Male 17(28.3) 
Female 43(71.7) 
Total 60(100) 
 
 
 
 
 
Figure 2: Sex distribution of patients studied 
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Duration of symptoms 
The mean duration of symptoms among Rheumatoid Arthritis patients 
was 17.88 months, ranging from 3 to 60 months, 35% of patients had 
symptom duration ranging from 11 to 20months. 
 
 
Table 3: Duration of symptoms 
 
Duration of symptoms 
(months) 
No. of 
patients(%) 
≤10 months 17(28.3) 
11months – 20 months 21(35.0) 
21 months – 30 months 13(21.7) 
 30 months 9(15.0) 
Total 60(100) 
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Figure 3: Duration of symptoms 
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Clinical features and investigations 
A positive history of joint pains, morning stiffness and joint swelling 
was elicited from every patient belonging to the study group. Patients with 
diabetes mellitus and hypertension, as well as those who gave history of 
symptoms suggesting cardiac, respiratory or renal diseases like chest pain, 
palpitation and breathlessness on exertion, pitting pedal edema, paroxysmal 
nocturnal dyspnoea (PND) or orthopnea were excluded from the study. Those  
with history of constitutional symptoms such as anorexia, fever and fatigue 
were included in the study. 
 
80 % of patients had history of morning stiffness lasting for over 60 
minutes. 
 
Constitutional symptoms were present in 70% patients.7 patients had 
rheumatoid nodules. Purpura was present in 2 patients.7 patients showed joint 
deformities. 
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Figure 4: Symptoms (other than joint pain and joint swelling) 
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Joints involved 
A total of 4 to 28 joints were affected in patients with rheumatoid 
arthritis with the mean value for tender joints being 11.2±6.671 and swollen 
joints being 13.067±6.362. Pain involving 4 – 15 joints was present in 71.7% 
of patient sand 66.4% showed edema involving 4-15 joints. 
 
 
Table 4.Number of tender joints 
 
NUMBER OF 
JOINTS 
NUMBER OF 
PATIENTS(%) 
≤10 32(53.33) 
11 – 15 11(18.3) 
16 – 20 12(20) 
> 20 5(8.3) 
Total 60(100) 
 
Table 5.Number of swollen joints 
 
NUMBER OF 
JOINTS 
NUMBER OF 
PATIENTS (%) 
≤10 25(41.7) 
11 – 15 15(25) 
16 – 20 12(20) 
> 20 8(13.3) 
Total 60(100) 
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Figure 5.No. of joints 
 
 
 
 
Pallor was observed in 8 patients, 7 patients showed deformities of the 
joints, 7 (11.7%) patients were found to have rheumatoid nodules, and 2 
patients (3.3%) had purpura. Rheumatoid factor (RF) was positive in 71.7% 
of patients (43 patients). The values of RF in the study were found to be 
ranging from 15 to 460 IU/dl. 
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Microalbuminuria 
In this study, microalbuminuria(MA) was present in 19 patients 
(31.7%), which included 3 males and 16 females. 
 
Table 6.Microalbuminuria 
MICROALBUMINURIA NUMBER OF PATIENTS (%) 
Present 19(31.7) 
Absent 41(68.3) 
Total 60(100) 
 
 
Figure 6.Microalbuminuria 
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Disease activity (DAS28) 
In this study, the disease activity as defined by DAS28 was moderate in 
19 patients (31.7%) and severe in 41 (68.3%). None had mild disease activity. 
 
Table 7.DAS28 
 
DAS28 NUMBER OF PATIENTS (%) 
Mild 0 
Moderate 19 (31.7) 
Severe 41 (68.3) 
Total 60 (100) 
 
 Figure 7.DAS28 
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Study parameters 
Table 8: Mean levels of study parameters(1) 
Study parameters 
Microalbuminuria 
 
P value Absent(n=41) Present(n=19) 
Age in years, mean ± SD 42.81±13.39 48.32±14.18 0.151 # 
Sex – male:female 10:31 7:12 0.492 # 
Morning stiffness   60 min, n(%) 32(78.05%) 16(84.21%) 0.835 ## 
Constitutional symptoms, n(%) 24(58.54%) 18(94.74%) 
 
0.005** 
Patients on treatment, n(%) 11 (26.83%) 
 
10 (52.63%) 0.031** 
Deformed joints 7(17.07) 0 >0.05** 
Rheumatoid nodules 4(9.76) 3(15.79) >0.05** 
Purpura 2(4.88) 0 >0.05** 
Duration of symptoms, mean ± SD 14.73±8.09 24.68±12.06 0.0004* 
Number of swollen joints, mean ± SD 11.76±6.31 15.89±5.64 0.018* 
Number of tender joints, mean ± SD 9.76±6.25 
 
14.32±6.64 0.0125* 
ESR, mean ± SD 50.12± 29.19 
 
80.16±26.67 0.0003* 
CRP, mean ± SD 14.63±14.85 27.23±21.26 0.0103* 
RAF, mean ± SD 73.63±64.39 187.95±141.27 ‹0.0001* 
DAS28, mean ± SD 5.2±0.63 6.73±0.65 ‹0.0001* 
 
* independent sample t test       # ## chi-square test 
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Of the 19 patients with microalbuminuria in this study, 16(84.2%) had 
morning stiffness, 18(94.7%) had constitutional symptoms, and 10 patients 
(52.6%) were on treatment with DMARDs or NSAIDs. 
The duration of symptoms was significantly greater in patients with 
microalbuminuria with mean value of 24.68±12.06 months when compared 
with 14.732±8.09 in patients with negative MA (p-0.0004).The mean value 
for swollen joints was 15.89±5.64 in microalbuminuria positive group when 
compared with 11.76±6.31 in microalbuminuria negative group(P-0.018).The 
mean value for tender joints was 14.32±6.64 in microalbuminuria positive 
group when compared with 9.76±6.25 in microalbuminuria negative group. 
The mean value for ESR was also found to be significantly greater in patients 
with microalbuminuria (80.16±26.67 v/s 50.12 ± 29.19), with p value 
0.0s003.The mean value for CRP was 27.23±21.26 in microalbuminuria 
positive group when compared with 14.63±14.85 in microalbuminuria 
negative group (P-0.0103). Only 3 out of 19 MA positive patients 
(15.79%)had negative RF. The mean value for RF was 187.95±141.27 in 
microalbuminuria positive group when compared with 73.63±64.39 in 
microalbuminuria negative group (P‹0.0001). The mean DAS28 score was 
6.73±0.65 in microalbuminuria positive group when compared with 5.2±0.63 
in microalbuminuria negative group (P‹0.0001) 
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Table 9: Mean levels of study parameters(2) 
 
Study parameters 
DAS28 
Moderate(n=19) Severe(n=41) 
Age in years, mean ± SD 45.26±12.44  44.22±14.48 
Sex – male:female  4:15  13:28 
Morning stiffness, n(%) 15(78.95%) 33(80.49%) 
Constitutional symptoms, n(%) 13(68.42%) 29(70.73%) 
Patients on treatment, n(%) 6(31.58%) 15(36.59%) 
Deformed joints, n(%) 5(26.32%) 2(4.88%) 
Rheumatoid nodules ,n(%)  3(15.79%) 4(9.76%) 
Petechiae, n (%) 2(10.53%) 0 
Duration of symptoms, mean ± SD 13.26±7.91  20.02±10.96  
Number of swollen joints, mean ± SD 11.79±6.76  13.66±6.16  
Number of tender joints, mean ± SD 9.86±7.16  
 
11.9±6.4  
ESR, mean ± SD 55.89±25.83  
 
61.37±33.99 
CRP, mean ± SD 19.64±16.65  20.01±19.12  
RAF, mean ± SD 111.21±85.99  109.19±188.49  
MA, mean ± SD 34.47±45.35 94.39±91.48 
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Out of the 60 patients who participated in this study, 19 were having 
moderate disease activity and 41 patients with severe disease activity 
according to the DAS28 score. The mean value for age in patients with 
moderate disease activity was 45.26±12.44 years while in patients with severe 
disease activity, it was found to be 44.22±14.48 years. Of the 48 patients with 
morning stiffness lasting more than an hour, 15 belonged to the moderate 
disease activity group and 33 had severe disease activity. Of the 42 patients 
with constitutional symptoms, 13 had moderate disease activity and 29 had 
severe disease activity. Of the 21 patients receiving treatment for RA, 6 
patients belonged to the moderate disease activity group and 15 patients 
belonged to severe disease activity group. 5 patients with moderate disease 
activity and 2 patients with severe disease activity showed deformity of 
joints. 3 patients with moderate disease activity and 4 patients with severe 
disease activity had rheumatoid nodules. Only 2 patients in the moderate 
disease activity group and none in the severe disease activity group showed 
presence of purpura. 
The duration of symptoms was higher in patients with severe disease 
activity with a mean value of 20.02±10.96 months when compared with 
13.26±7.91  in patients with moderate disease activity.  
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The mean value for swollen joints was 13.66±6.16 in severe disease 
activity group when compared with 11.79±6.76  in moderate disease activity 
group. The mean value for tender joints was 11.9±6.4 in severe disease 
activity group when compared with 9.86±7.16 in moderate disease activity 
group. 
The mean value for ESR was found to be 55.89±25.83 in patients with 
moderate disease activity when compared with 61.37±33.99 in patients with 
severe disease activity. The mean value for CRP was 19.64±16.65 in 
moderate disease activity group when compared with 20.01±19.12 in severe 
disease activity group. 
The mean value for RF was found to be 111.21±85.99 in the moderate 
disease activity group and 109.19±188.49 in the severe disease activity group. 
The mean value for MA was found to be 34.47±45.35 in the moderate disease 
activity group and 94.39±91.48 in the severe disease activity group. 
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Age and microalbuminuria 
Microalbuminuria was observed to be more frequent in the study 
population aged above 50 years. P value was not significant (0.628). 
 
Table 10: Association of age in years with presence of microalbuminuria 
Age in years Number of patients 
Microalbuminuria  
P value 
Absent Present 
‹ 30 9 7 2 
0.628 
31 – 40 11 8 3 
41 – 50 22 15 7 

 50 18 11 7 
Total 60 41 19  
 
 
Chi-square value for trend is 0.235, degree of freedom 1 and p-value 0.628. 
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Figure 8: Association between age (years) and Microalbuminuria 
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Sex and microalbuminuria 
 
Among the 19 patients in whom microalbuminuria was found to be 
present, there were 7 males and 12 females. There was no significant 
association between microalbuminuria and gender of the patient                             
(p value=0.492) 
 
Table 11: Association of sex with presence of microalbuminuria 
Sex Number of patients 
microalbuminuria 
P value 
Absent Present 
Male 17 10 7 
0.492 
Female 43 31 12 
total 60 41 19  
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     Figure 9: Association between sex and Microalbuminuria 
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Duration of symptoms and microalbuminuria 
Out of the 19 patients who tested positive for the presence of 
microalbuminuria, 8 patients (42.1%) had symptoms lasting for 21 – 30 
months and 6 patients (31.6%)had symptom duration of more than 30 months 
(31-60 months). 73.7% of patients were seen to have symptoms lasting for 
more than 20 months. 
 
Table 12: Association between duration of symptoms and 
Microalbuminuria 
Duration of symptoms (months) No. of patients 
Microalbuminuria  
P value 
Absent Present 
 
≤10 months 17 15 2 
0.0394 
11months – 20 months 21 18 3 
21 months – 30 months 13 5 8 
 30 months 9 3 6 
Total 60 41 19  
 
 
P value was significant (0.0394) in patients with symptoms >30 months. 
Chi-square value for trend is 4.242, degree of freedom 1 and p-value is 
0.0394. 
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Figure 10: Association between duration of symptoms and          
Microalbuminuria 
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Limbs and microalbuminuria 
 
Out of the 19 patients who had microalbuminuria, 2 patients had 
involvement of the upper limbs alone, none showed involvement of lower 
limbs alone, and 17 patients had involvement of both upper limb and lower 
limb joints. There was no statistically significant association found between 
any of the groups (p value >0.05). 
 
 
 
  Table 13: Association between  limb invovement and Microalbuminuria 
 
 
Limbs involved Number of patients 
Microalbuminuria  
P value Absent Present 
 
Both upper limbs 14 12 2 
>0.05 Both lower limbs 4 4 0 
All four limbs 42 25 17 
Total 60 41 19  
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Figure 11: Association between involvement of limb joints and    
Microalbuminuria 
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Morning stiffness and microalbuminuria 
 
Duration of morning stiffness was found to be lasting for a 
significantly longer period in those patients having microalbuminuria. 
Out of the 19 patients with microalbuminuria, 16 patients had morning 
stiffness for more than 60minutes, 2 patients had between 30 minutes and 60 
minutes, 1patient had morning stiffness lasting less than 30 minutes. But there 
was no significant association statistically.(The Chi-square value for trend is 
0.043 at degree of freedom 1 with p-value of 0.8351). 
 
Table 14: Association between morning stiffness and Microalbuminuria 
Duration of morning stiffness Number of patients 
Microalbuminuria  
P value 
Absent Present 
 
‹ 30 min 4 3 1 
0.835 30–60 min 8 6 2 

 60 min 48 32 16 
Total 60 41 19  
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Figure 12: Association between morning stiffness and Microalbuminuria 
 
 
 
 
 
 
  
3
6
32
1
2
16
0
5
10
15
20
25
30
35
‹ 30 MIN 30 - 60 MIN › 60 MIN
ABSENT 
PRESENT
 68 
 
ESR and microalbuminuria 
 
In microalbuminuria positive group, the mean value of ESR was 
80.158±26.671, while in microalbuminuria negative group it was 
50.122±29.194; this was seen to be statistically significant. Significantly 
higher values of ESR were observed in patients with positive 
microalbuminuria. 17 out of the 19 patients with microalbuminuria had ESR 
values above 50; and 7 had values above 100. 
 
       Table 15: Association of ESR with presence of Microalbuminuria 
ESR Number of patients 
Microalbuminuria  
P value 
Absent Present 
≤ 50 23 21 2 
0.0012 51 –100 29 19 10 
  100 8 1 7 
Total 60 41 19  
 
 
The Chi-square value for trend is 10.488, degree of freedom is 1 and p-
value 0.0012. 
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Figure13: Association between ESR and Microalbuminuria 
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CRP and microalbuminuria 
In microalbuminuria positive group, the mean value of CRP was 
25.647±22.67 mg/l, while in microalbuminuria negative group it was 
17.219±15.366 mg/l.(p-0.0103).Significantly higher values of CRP were 
observed in patients with positive microalbuminuria.Out of the 19 patients 
with MA, 16 had positive CRP values. Out of the 19 patients who had 
microalbuminuria positive, CRP value was ≤ 30 mg/l in 10 patients, between 
30 and 60 mg/l in 8 patients, and › 60 mg/l in one patient. 
 
Table 16: Association of CRP with presence of Microalbuminuria 
CRP(mg/l) Number of patients 
Microalbuminuria  
P value 
Absent Present 
≤ 30 44 34 10 
0.0308 31 –60 15 7 8 

 60 1 0 1 
Total 60 41 19  
 
Chi-square value for trend is 4.664, degree of freedom 1 and p value 0.0308 
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Figure 14: Association between CRP levels and Microalbuminuria 
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Rheumatoid factor and microalbuminuria 
Out of the 19 patients who have microalbuminuria, only 3 were 
negative for rheumatoid factor. In microalbuminuria positive group, the mean 
value of RF was 187.947±141.269IU/l, while in microalbuminuria negative 
group it was 73.627±64.398 IU/l, with a p value of ‹0.0001. 
 
 
   Table 17: Association RA Factor with presence of Microalbuminuria 
 
RA factor Number of patients 
Microalbuminuria  
Absent Present 
 
Negative 17 14 3 
    Positive 43 27 16 
   Total 60 41 19 
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Figure 15: Association between RA Factor and Microalbuminuria 
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Extra-articular manifestations and microalbuminuria 
9 out of the 60 patients who participated in this study showed extra 
articular manifestations – 7 had rheumatoid nodules and 2 had purpura. Only 
3 patients with rheumatoid nodules had microalbuminuria. Patients with 
purpura did not test positive for microalbuminuria. There was no statistically 
significant association between microalbuminuria and extra-articular 
manifestations. Of the 9 patients with extra articular manifestations,8 patients 
had positive RF. 
 
 
Table 18: Association of extra-articular manifestations with 
microalbuminuria 
 
 
EAM Number of patients 
Microalbuminuria  P value 
Absent Present 
 
>0.05 
Rheumatoid nodules 7 4 3 
Purpura 2 2 0 
Total 9 6 3  
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Figure 16: Association of extra-articular manifestations with 
microalbuminuria 
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Drugs and microalbuminuria 
 
21out of the 60 (35%) patients who participated in this study were on 
treatment –7 patients were on NSAIDs alone, 4 patients on NSAIDs+HCQS, 
one patient was on NSAIDs+HCQS+ STEROID, 6 patients were on 
NSAIDs+ HCQS+ METHOTREXATE, and3 patients were on NSAIDs+ 
HCQS+ STEROID+METHOTREXATE. Out of the 21 patients receiving 
treatment, 10 showed positive microalbuminuria. 
 
Table 19: Association of drugs used with presence of microalbuminuria 
 
Drugs Number of patients 
Microalbuminuria 
Absent Present 
 
No or irregular treatment 39 30 9 
NSAIDS 7 4 3 
NSAIDS + HCQS 4 3 1 
NSAIDS + HCQS + STEROID 1 0 1 
NSAIDS + HCQS + MTX 6 3 3 
NSAIDS + HCQS + STEROID + MTX 3 1 2 
Total 60 41 19 
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DAS 28 and microalbuminuria 
In microalbuminuria positive group, the mean value of DAS28 was 
6.73±0.65, while in microalbuminuria negative group it was 5.2±0.63, with a 
significant p value of 0.003. Of the 19 patients with microalbuminuria, 18 
(94.74%) had severe disease activity according to DAS28 score. 
 
Table 20: Association of DAS28 and presence of Microalbuminuria 
DAS28 Number of patients 
microalbuminuria 
P value 
Absent Present 
Moderate disease activity 19 18 1 
0.007 
Severe disease activity 41 23 18 
Total 60 41 19  
 
The Chi-square value for trend is 7.261 with degree of freedom 1 and p-value 
of0.007 
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Figure 17: Association of DAS28 and Microalbuminuria 
 
 
 
 
  
18
23
1
18
0
5
10
15
20
25
MODERATE DISEASE ACTIVITY SEVERE DISEASE ACTIVITY
ABSENT
PRESENT
 79 
 
 
DISCUSSION 
This study was done to investigate,  
• The prevalence of microalbuminuria inpatients with Rheumatoid 
Arthritis, 
• The relationship between microalbuminuria and disease activity in 
Rheumatoid Arthritis as assessed by DAS28. 
Our study was conducted in Thanjavur Medical College, Thanjavur. 
Being a tertiary care centre, the patients attending the outpatient department 
include all those referred from other centres. The average number of patients 
attending our Rheumatology OPD, on Tuesdays and Thursdays every week, 
is 100. These include nearly all connective tissue disorders like Rheumatoid 
Arthritis, Systemic Lupus Erythematosus, Sjogren’s syndrome, mixed 
connective tissue disorders, etc. About 30 patients with Rheumatoid Arthritis 
attend the OPD daily, out of which 10-20% are new patients attending the 
clinic for the first time. These patients are either undiagnosed previously or 
diagnosed and referred from other centres.20-30% patients were our own 
patients on regular follow up. 30-40% patients were those on irregular follow 
up. The irregular follow up in majority of them was due to financial 
difficulties. The Rheumatoid Arthritis patients in our study were seen to have 
either moderate or severe disease activity as defined by DAS28 score. This 
may possibly be due to the reason that this institution being a tertiary health 
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care level will have only referred cases. The duration of symptoms in every 
one of them was less than five years. 
In the present study, the mean age of the population was 44.55 years. 
Maximum number of patients was in the 41-50 age groups. The mean value 
for age in both microalbuminuria positive and negative group was similar, 
48.32±14.18 and 42.81±13.39 respectively. The mean value for age in 
females was 43.77yrs(SD-14.128) whereas in males it was 46.53 yrs (SD-
13.005). This is according to the observation by Akil M et al12that occurrence 
of Rheumatoid Arthritis is highest in the forties. 
In the present study, age was not a significant factor for MA (P- 
0.151).Pederson L M et al also got similar results.100 
Among the participants in this study, there were 43females (71.7%) 
and 17males (28.3%), with a female to male ratio of 2.53. This is a bit lower 
than the usually observed ratio of 3:1. 
The mean duration of symptoms among Rheumatoid Arthritis patients 
in this study was 17.88 months. Most of the patients (35%) had symptom 
duration ranging between 11-20 months. 80% of the patients gave a definite 
history of morning stiffness of more than 1 hour duration. 70% patients had 
constitutional symptoms. Rheumatoid nodules were present in 11.67% of 
patients. Joint deformity and purpura were observed in 11.7% and 3.3% of 
patients respectively. 
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A total of 4 to 28 joints were involved in patients with rheumatoid 
arthritis with the mean value for tender joints being 11.2±6.671 and swollen 
joints being 13.067±6.362. 71.7% of patients had 4 – 15 painful joints and 
66.4%  patients had edema of 4 – 15 joints. 
In this study, 19 patients (31.67%) had microalbuminuria out of which 
12 were females and 7 were males. There was no significant difference in sex 
distribution between microalbuminuria positive and negative groups (p- 
0.365).In the study by Pederson L M et al, they observed that there is no 
difference in the median ratio of albumin excretion between males and 
females in Rheumatoid Arthritis patients (p-0.1).100 Similar observation was 
made by Monica Verma et al105 also. 
We observed that out of the 19 patients with positive 
microalbuminuria, 18 patients showed presence of constitutional symptoms 
like anorexia, fever and tiredness (p-0.0054). In our study, out of the 19 
patients having microalbuminuria, 16 (84.2%) patients had morning stiffness 
lasting more than one hour; but there was no significant statistical association 
between morning stiffness and microalbuminuria. From the currently 
obtained data, it suggests that microalbuminuria is an indicator of severe 
disease activity. 
9 patients in our study had extra articular manifestations in the form 
of purpura (2) and rheumatoid nodules (7). Rheumatoid nodules was found to 
be the most common extra articular manifestation in this study, similar to the 
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observations made in the studies by Turesson115 et al. Tests for detecting 
microalbuminuria was positive only in 3 patients with rheumatoid nodules 
and none with purpura. No significant statistical association was found 
between MA and EAM. In view of the fact that the majority of the patients 
were having shorter disease duration, it is difficult to comment about the 
relationship between microalbuminuria and EAM. 8 out of the 9 patients with 
EAM had positive RF. This is also according to the studies by Turesson 114 et 
al. 
The prevalence of microalbuminuria in Rheumatoid Arthritis was 
found to be 31.7% in our study. This was similar to the findings obtained in 
other studies including Pederson L M et al and Bhatt G et al.According to 
Pederson L M et al 100, the prevalence of microalbuminuria in Rheumatoid 
Arthritis was 27.7%. Bhatt G etal101observed the prevalence of 
microalbuminuria to be 30%. In the studies by Monica Verma et al105, the 
relative occurrence of microalbuminuria in Rheumatoid Arthritis patients was 
26%. 
In our study, there were no age and sex matched controls since this 
was not a case control study. However in the study conducted by Pederson L 
M et al100and Bhatt G et al101, the prevalence of microalbuminuria was 
significantly more in Rheumatoid Arthritis cases 27.7% v/s 7.8% in age and 
sex matched controls and 30% as compared to 5% in age and sex matched 
controls, respectively. According to Monica Verma et al105, the relative 
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incidence of microalbuminuria in rheumatoid arthritis patients was 26% as 
against 4% in controls. 
Saito M et al compared the urinary albumin indices in patients having 
Rheumatoid Arthritis ,osteoarthritis and normal control subjects and observed 
that the urinary albumin indices were 25.7+/-38.2, 11.4+/-11.5 and 7.7+/-3.5 
respectively, significantly greater in patients with Rheumatoid Arthritis.102 
Sihvonen et al in 2004 saw that microalbuminuria was present in 34 
out of 600 Rheumatoid Arthritis patients and 27 out of 470 controls. 
Rheumatoid Arthritis patients with microalbuminuria were seen to have 
higher mortality rate when compared with those patients without MA, with a 
hazard ratio of 2.77 in MA positive patients.28 These observations suggests 
that microalbuminuria is comparatively common in patients with Rheumatoid 
Arthritis. 
In inflammatory diseases, there seems to be increased systemic 
vascular permeability to plasma proteins. Hence, excretion of microalbumin 
in urine is indicative of a systemic response in cases of an acute phase 
reaction 101. The increased rate of albumin excretion in RA can either be due 
to its inflammatory effect on vascular permeability or due to the side effects 
caused by the nephrotoxic drugs used for the disease therapy. Renal 
complications are more in Rheumatoid Arthritis patients,3031 and higher 
mortality is observed in the presence of proteinuria.32So, it is essential to have 
a sensitive method for reliable clinical measurement of dysfunction of the 
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kidneys. The present study confirms the occurrence of pathological 
albuminuria in several RA patients without any history suggestive of renal 
dysfunction, diabetes or hypertension. This is consistent with the earlier 
reports regarding subclinical renal dysfunction in RA. 17 
The reversible subclinical stage of renal disease may stay unnoticed 
for a long duration, and it’s necessary to detect it at the earliest31. The usual  
measures used for measuring kidney function like urine total protein assays, 
urine dipstick testing, urine cytology and serum creatinine may not identify 
mild to moderate damages to the kidneys. Every patient having 
microalbuminuria in this study showed normal levels of serum creatinine, 
macroalbuminuria was absent and also showed normal 24 hour urine protein. 
Estimation of urine albumin levels by immunoturbidimetry or other 
immunochemical methods is a simple and sensitive method for identifying 
early subclinical damage to the kidneys. 29 
RA patients in this study belonged either to the moderate or severe 
disease activity group categorised according to the DAS28 score. This may be 
due to the reason that being a tertiary care centre, more of referred cases are 
seen here. 
In this study, it was found that there is significant association between 
ESR and MA. In microalbuminuria positive group, the mean value of ESR 
was 80.158±26.671, while in microalbuminuria negative group it was 
50.122±29.194 (p-0.0003). 17 out of the 19 patients (89.47%) with 
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microalbuminuria had ESR values above 50; and 7 (36.84%) had values 
above 100. Results in our study showed that MA increases with increasing 
ESR levels. According to Monica Verma et al105, there is significant 
relationship between MA and ESR (p <0.001). Pederson L M et al observed 
no statistically significant association between ESR and MA in patients with 
Rheumatoid Arthritis, even though elevated ESR levels were observed in 
patients having microalbuminuria. This could be partly due to the reason that 
some patients with normal urine albumin levels showed elevated ESR levels 
for causes other than rheumatoid arthritis. Another explanation given by them 
was that majority of the patients in the study were already on treatment with 
DMARDs 100. 
In our study, the mean value for CRP was 25.65±22.67in MA positive 
patients 
when compared to 17.22±15.37 in MA negative patients(p-0.0301). 
Significantly elevated levels of CRP were observed in patients having MA. 
Out of the 19 patients with MA, 16(84.2%) showed positive CRP results. Of 
the 19 patients with microalbuminuria, CRP value was ≤ 30 mg/l in 10 
patients, between 30 and 60 mg/l in 8 patients, and › 60 mg/l in one patient. 
In our study, it was found that levels of microalbuminuria increases as 
the CRP levels increase suggesting a direct association between the two. As 
elevated ESR and CRP are markers of severe disease, microalbuminuria also 
suggests a severe disease. In the study by Nakamura et al103, CRP levels 
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representing low grade inflammation was found to be significantly associated 
with microalbuminuria. Pederson L M et al100also got similar results and 
observed that the median values (ranges between) were 112 (16-1615) nmol/l 
for CRP and also that CRP was significantly associated with UACR. 
Significant relationship between MA and CRP was also noted by Bhatt G et 
al101, and Moniva Verma et al105. 
In this study, only 3(15.79%) patients in MA positive group had RA 
factor negative, while 16(84.21%) had positive RF. In microalbuminuria 
positive group, the mean value of RF was 187.947±141.269IU/l, while in 
microalbuminuria negative group it was 73.627±64.398 IU/l, with a p value 
of ‹ 0.0001. 
A significant association was observed between RA factor and 
microalbuminuria in our study. Similar results were also obtained by Gordon 
et al58, Turesson et al5960 and Young et al61, and found that RA factor was 
generally absent in patients with milder disease. This indicates that 
microalbuminuria is related with severe disease activity. 
According to this study, the mean value for swollen joints was 
15.89±5.64 in microalbuminuria positive group when compared with 
11.76±6.31 in microalbuminuria negative group (P-0.018), and the mean 
value for tender joints was 14.32±6.64 in microalbuminuria positive group 
when compared with 9.76±6.25 in microalbuminuria negative group( p-
0.0125). These results suggest that microalbuminuria is significantly 
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associated with disease activity in RA. Similar number of joints was involved 
in the study by Monica Verma et al105(p< 0.05,). However in this study, no 
significant relationship was found between occurrence of microalbuminuria 
and the limb involved (upper or lower limb or both). 
In this study, it was observed that the mean duration of symptoms was 
significantly more in MA positive group (24.68±12.06) than MA negative 
group with a p value of 0.0004. Same results are obtained by statistical 
analysis suggesting that microalbuminuria increases with increase in disease 
duration. Hence, patients having symptoms for a longer period are more 
prone to have microalbuminuria. 
In the study by Pederson L M et al100, results indicate that patients 
having microalbuminuria had significantly longer median disease duration 
than the group with normal UACR. Similar results were also in the studies by 
Bhatt G et al101 and Monica Verma et al 105. 
The relationship between MA and disease duration may be either due 
to severe and chronic disease affecting the kidneys increasing the 
permeability of systemic vessels, or due to the additional nephrotoxic therapy 
given to the patients having severe chronic disease. 
Our study showed significant association between MA and DAS28 
score. The mean DAS28 score was 6.73±0.65 in microalbuminuria positive 
group when compared with 5.2±0.63 in microalbuminuria negative group 
(p‹0.0001). Out of the 19 patients having microalbuminuria, 18 (94.74%) had 
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severe disease activity. There was statistically significant association between 
MA and DAS28 score with a p value of 0.007. The mean value for MA was 
found to be 34.47±45.35 in the moderate disease activity group and 
94.39±91.48 in the severe disease activity group. This difference was also 
observed to be statistically significant with a p value 0.009. Observations 
made by Harkrishnan Aggarval et al111and V Raveendran et al112 were also 
similar. 
In our study, we got statistically significant association between drug 
therapy and the presence of MA .Out of the 19 patients with MA, 10 were on 
treatment with DMARDs or NSAIDs or both. In the study by Pederson L M 
100
, MA was found to be significantly more in patients treated with gold and 
pencillamine. Also in the study by Bhatt G 101 et al, treatment with NSAIDs, 
methotrexate, salazopyrene, chloroquine and steroids was found to be 
significant. However, these patients have severe disease activity and longer 
duration of disease. 
The mean values for DAS28 score, CRP, ESR and RF were higher in 
the patients having microalbuminuria than those who do not have. Moreover, 
the number of swollen/tender joints, and duration of symptoms were found to 
be more in patients with MA. MA was noted to be significantly associated 
with these parameters. Since ESR, CRP, and DAS28 are considered as 
indicators of disease activity, presence of MA indicates a severe disease. 
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Microalbuminuria and subclinical damage to the kidneys are more 
common in RA especially in those having greater disease duration. Routine 
investigations like serum creatinine may not be helpful in identifying 
subclinical damage to kidneys100. Since microalbuminuria is a good predictor 
of kidney dysfunction, our study shows that subclinical renal disease is 
frequently observed in Rheumatoid Arthritis patients. Still, the long term 
prognosis for renal involvement in rheumatoid arthritis patients needs to be 
clarified by means of longitudinal studies. We think that in most of the 
patients having microalbuminuria in RA, renal involvement is reversible and 
the chances of developing end stage renal disease is scarce if timely 
intervention done. 
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                                     CONCLUSIONS 
About one third of the patients having rheumatoid arthritis is seen to 
have microalbuminuria. 
In this study microalbuminuria was found to be significantly 
associated with disease activity in rheumatoid arthritis as assessed by DAS28, 
ESR, CRP and RA Factor. Microalbuminuria is also found to be associated 
with  duration of disease and presence of active symptoms. There was no 
significant association between gender, age and drugs with microalbuminuria. 
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                                               ANNEXURE 1 
Proforma for the study on prevalence of microalbuminuria in rheumatoid arthritis 
and its association with disease activity 
 
PATIENT PROFILE 
 
Name Age(in years)               Sex-male/female 
Occupation 
Address 
Phone no 
Op no                                                                                              Date 
 
Presenting Complaints 
 
1.Pain in small joints of hand  
Present/absent 
Unilateral/bilateral 
Duration(months)□ 
 
2.Morning stiffness  
<30 min □30-60 min □>60 min □ 
3.Constitutional symptoms  
fever□anorexia □tiredness □ 
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4.Pain in other joints 
UPPER LIMB□LOWER LIMB□ BOTH □ 
5. Other joints involved(if any) □Duration(months)□ 
6. Deformities – present/absent 
If present, duration (in months)□ 
Past history 
Family history - Rheumatoid Arthritis□Hypertension□Diabetes□ 
Personal history 
Diet-veg□nonveg□mixed□ 
Appetite-normal□increased□decreased□ 
Sleep- normal□increased□decreased□ 
Bowel 
Bladder 
Smoking-yes□no□ 
Alcohol-yes□no□ 
Treatment history 
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GENERAL EXAMINATION 
Built-poor □moderate □well□ 
Nourishment-poor □moderate □well □ 
Pallor-yes □no □ 
Icterus-yes □no □ 
Cyanosis-yes □ no□ 
Clubbing-yes □ no□ 
Lymphadenopathy –yes □ no□ 
Edema –yes □ no□  
Oral cavity  
height(cm)                  weight(kg) 
pulse BPJVPyes □no □ 
Temp  RR 
Rheumatoid nodules□Otherextra articular manifestations□ 
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LOCAL EXAMINATION 
Deformities – yes □no □ 
Restriction – yes □no □ 
 
SYSTEMIC EXAMINATION 
 
Cardiovascular system 
Inspection  
Palpation  
Percussion  
Auscultation 
 
Respiratory System 
Inspection  
Palpation  
Percussion  
Auscultation 
 
Gastrointestinal Tract 
Inspection  
Palpation  
Percussion  
Auscultation 
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            Central Nervous System 
HMF 
Speech 
Cranial nerves 
Motor system 
Sensory system 
Reflexes  -superficial 
                - deep 
 
INVESTIGATIONS 
• Blood Routine Examination 
• Urine Routine Examination 
• Blood urea 
• Serum creatinine 
• Chest X-ray 
• ECG 
• CRP 
• RA factor 
• RBS 
• Urine p/c 
• 24 hour urine protein 
• DAS28 score 
• VAS score (mm) 
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CONSENT FORM 
 
 
 
I __________________________________________  hereby give consent to 
participate in the study conducted on prevalence of microalbuminuria in 
Rheumatoid arthritis and its relation with disease activity in the Department 
of  General Medicine ,Thanjavur Medical College & Hospital, Thanjavur – 
613004 and to use my personal clinical data and result of investigation for the 
purpose of analysis and to study the nature of disease. I also give consent for 
further investigations 
 
 
Place : 
Date :       Signature of participant 
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INFORMATION SHEET 
 
We are conducting a cross sectional study on a study of prevalence of 
microalbuminuria in rheumatoid arthritis and its association with 
disease activity in the Department of General Medicine, Thanjavur medical 
college and hospital, Thanjavur – 613004. 
At the time of announcing the results and suggestions, name and identity 
of the patient will be confidential. 
Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not 
result in any loss of benefits to which you are otherwise entitled. 
The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may aid 
in the management or treatment. 
 
Signature of Investigator                                          signature of participant  
 
Date: 
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                            KEY TO THE MASTER CHART 
 OP-out patient number 
 Duration-duration of symptoms in months 
 TJ –number of tender joints involved 
 SJ-number of swollen joints involved 
 Limb-limbs involved- QL-all four limbs, BUL-both upper limbs only, 
BLL-both lower limbs only 
 Morning stiffness-duration of morning stiffness in hour 
 Constitutional symptoms-0-absent, 1-present 
 Treatment – drugs taken by patients, N-no/irregular treatment, 
NSAID-nonsteroidal anti-inflammatory drugs, MTX-methotrexate, 
HCQS-hydroxychloroquin,STEROID-steroid 
 DJ-joint deformity- 1- present, 0-absent 
 EAM-extraarticular manifestations-RN-rheumatoid nodules, P-purpura 
 VAS-visual analogue scale score in millimeters 
 ESR-erythrocyte sedimentation rate in centimeters/hour 
 CRP-C-reactive protein in milligram/litre 
 U.ACR-urine albumin-creatinine ratio in microgram per milligram 
 RF- rheumatoid factor in international units/deciliter 
 DAS28-disease activity score 
 B.Ur-blood urea in mg/dl 
 S.Cr.-serum creatinine in mg/dl
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Anjamma F 55 102818 8 4 8 QL › 1 1 N 0 0 75 8 18 15 29 5.62 33 1 
Jagadhambal F 50 152290 22 16 18 QL › 1 1 N 0 RN 60 67 45 100 158 6.93 24 1 
Uthayarai F 43 151407 18 20 22 QL › 1 1 NSAIDs 0 0 82 90 49 36.5 21 5.79 33 0.9 
Arumugam M 64 135323 7 4 4 QL ‹ 0.5 0 N 0 0 66 10 3 23 18 5.41 36 0.8 
Vlarmathi F 48 152361 12 14 16 QL › 1 1 N 0 0 54 10 5 15 28 5.55 37 0.9 
Anjalaidevi F 54 151904 24 14 14 QL › 1 1 NSAIDs + HCQS 0 0 50 55 15 30 288 6.71 32 0.8 
Sutha F 50 6171 14 16 18 QL › 1 1 NSAIDs + HCQS +MTX 0 0 68 9 6 20 19 5.51 24 0.7 
Povinammal F 20 152423 24 18 24 BUL › 1 0 N 0 0 88 45 2 60 27 6.22 25 0.8 
Jayanthi F 55 144502 10 12 16 QL › 1 1 NSAIDs 1 0 80 40 7.7 140 22 4.15 24 0.7 
Sekar M 38 150642 12 6 8 QL › 1 1 N 0 0 74 42 4.9 61 25 5.61 22 0.8 
Rajenthiran M 44 1062 6 8 12 BLL › 1 1 N 0 P 52 91 4 40 27 4.36 34 0.6 
Manikyanagam M 43 81852 24 16 18 QL › 1 0 N 0 0 90 110 13 440 123 6.37 35 0.9 
Kumutha F 58 58029 4 4 4 BUL › 1 1 N 0 0 85 64 2.6 175 29 4.95 33 0.9 
Papa F 60 6671 26 28 28 QL ‹ 0.5 1 NSAIDs 0 RN 71 61 33 255 221 4.95 36 0.8 
Thiyagaran  M 31 157316 24 26 28 QL .5 – 1 0 N 0 0 78 67 33 96 18 4.97 34 0.9 
Anushiya F 53 155283 6 8 12 QL .5 – 1 0 NSAIDs + HCQS +MTX 1 0 52 60 27 102 23 4.87 34 0.9 
Saniyamal F 72 157725 22 8 10 QL › 1 1 N 0 0 69 50 14.8 27 129 6.47 33 0.7 
Maheshwari F 27 11435 16 12 14 BUL › 1 1 N 0 0 85 16 38 30 27 5.04 32 0.7 
Sumathi F 31 173160 18 12 14 QL › 1 1 NSAIDs + HCQS 0 0 77 30 5.9 51 17 4.53 25 0.8 
Indhra F 62 173114 3 4 4 QL › 1 1 N 0 0 59 95 54 40 29 4.34 26 0.8 
Saithabeevi F 48 156771 21 20 22 QL › 1 1 NSAIDs + HCQS +MTX 0 RN 64 105 14 353 212 6.81 33 1.1 
Venu M 44 1728301 13 12 14 BLL › 1 0 N 1 0 61 48 11 59 16 5.54 35 1.1 
Chithra F 36 163162 34 22 24 BUL › 1 1 N 0 0 90 100 5 40 29 5.92 25 0.9 
Thangavel M 42 67206 33 20 20 QL › 1 1 NSAIDs + HCQS + 
STEROID  
0 0 46 62 54 152 222 6.22 37 1 
Subhramanyan M 24 66993 7 4 6 BUL › 1 1 N 0 0 58 121 5 440 150 6.1 33 1 
Annailakshmi F 72 152151 6 4 6 QL › 1 0 N 0 0 65 40 8 31 11 6.37 35 1 
Periyanayaki F 43 54312 8 6 8 BUL › 1 1 N 0 RN 72 65 2.8 175 29 4.87 37 1.1 
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Aishabeevi F 29 195313 9 6 8 QL › 1 1 N 0 0 35 55 49 175 129 7.37 32 1.1 
Selvamani M 49 295 9 6 8 QL .5 – 1 1 N 0 0 44 90 50 90 28 5.45 31 0.9 
Lakshmimaniyal F 39 150624 9 8 8 BUL › 1 0 NSAIDs + HCQS + 
STEROID+MTX 
0 0 76 10 3.8 34 25 5.38 31 0.9 
Latheef M 50 98651 9 4 6 QL › 1 1 N 0 P 52 60 21 125 27 5.07 30 0.8 
Nagavali F 62 444 16 8 8 QL › 1 1 N 1 0 38 106 39 191 23 5.06 35 0.8 
Chellama F 14 178967 14 8 8 BLL .5 – 1 0 NSAIDs + HCQS 0 0 65 30 5.8 23 26 5.51 30 0.6 
Ambika F 34 190057 30 22 24 BUL › 1 1 N 0 0 60 100 1 55 22 5.31 34 0.6 
Nazeerahammed M 44 200572 10 4 8 QL ‹ 0.5 1 N 0 0 83 45 4 35 27 5.55 33 0.8 
Tamil Selvi F 49 33614 13 12 16 QL › 1 1 N 0 0 48 80 6 190 109 7.59 31 0.8 
Mllika F 24 05756 14 6 8 BUL › 1 0 N 0 0 58 82 19 53 23 5.41 36 0.7 
Devika F 33 156822 13 4 6 QL › 1 1 NSAIDs + HCQS +MTX 0 0 56 20 3.46 153 21 5.79 40 0.9 
Manokar M 43 126765 31 16 16 QL › 1 1 NSAIDs 0 0 64 103 7.7 20 134 6.33 34 0.7 
Ramayaan M 38 160544 22 12 14 QL .5 – 1 1 NSAIDs 0 0 76 60 70 125 151 6.32 35 0.9 
Fathimabhanu F 42 30755 21 8 14 QL › 1 1 NSAIDs + HCQS +MTX 0 0 85 34 31 380 189 7.32 33 0.9 
Aathimulam M 81 10376 36 20 20 QL › 1 1 NSAIDs + HCQS + 
STEROID+ MTX 
0 0 88 65 5.9 121 263 7.65 36 1.1 
Vijaya F 49 173384 10 4 12 QL .5 – 1 0 N 0 RN 76 46 8.9 64 20 4.67 34 0.8 
Priya F 27 234032 10 6 8 BLL › 1 0 N 1 0 70 34 5.8 35 30 4.87 35 0.7 
Sawndharya F 50 233920 60 28 26 QL › 1 1 NSAIDs + HCQS + 
STEROID+MTX 
0 0 60 110 50 130 278 6.47 32 0.7 
Shahunthala F 39 195970 12 10 14 QL › 1 1 NSAIDs + HCQS +MTX 0 0 47 70 0.4 359 297 6.76 33 0.6 
Kavitha F 50 235633 13 4 8 BUL › 1 0 N 0 0 54 10 3 28 23 5.04 32 0.9 
Balu M 43 238986 14 4 6 QL › 1 1 N 0 0 78 70 18.5 50 27 4.36 24 1 
Vijayakumar M 53 112662 16 6 8 QL › 1 1 N 1 RN 83 15 4 24 28 5.61 25 0.9 
Ilanjiyan F 41 105775 14 8 14 BUL › 1 1 NSAIDs + HCQS 0 0 65 62 18 330 23 4.15 24 0.9 
Pushpalatha F 36 290 30 16 16 QL ‹ 0.5 0 N 0 0 50 21 5 18.2 26 6.3 22 0.8 
Vidhyalekshmi F 51 147633 11 8 8 QL › 1 0 N 1 0 58 25 36 26 22 3.26 26 0.6 
Dhanalakshmi F 32 59300 18 12 14 BUL › 1 1 N 0 0 86 120 39 150 101 6.75 34 0.6 
Saraswathi F 23 11192 34 18 14 BUL › 1 1 NSAIDs 0 0 81 60 25 160 18 4.93 35 0.7 
Amutha F 43 20348 32 20 20 QL › 1 0 N 0 0 68 65 3 121 29 5.31 30 0.8 
Kalavathidevi F 17 210473 22 14 16 BUL .5 – 1 0 NSAIDs 0 0 45 55 5 50 17 5.55 34 1 
Ravathi F 53 146174 15 6 8 QL › 1 1 N 0 0 66 54 14.8 59 18 5.41 33 1.1 
Selvapani F 57 168949 32 10 12 QL .5 – 1 1 N 0 0 72 105 53 39 177 7.08 32 1.1 
Kaliyamoorthy M 60 174916 36 12 12 QL › 1 1 N 0 0 55 90 11.5 85 222 7.59 35 0.9 
Nandhini F 59 205039 16 4 4 QL › 1 0 N 0 RN 65 65 19 85 25 5.61 25 0.8 
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